Medication campaign to eliminate malaria in nearby villages
Part of Infections clinical trials.
This Phase 3 trial tests whether giving malaria medicine to people in high-risk households (a “mass drug administration” campaign) can stop local relapses and eliminate vivax malaria. If you live close to a recent malaria case, you may be offered a preventive dose, based on age and medical safety checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Live within 200 meters of a past vivax malaria case household (within the last 2 years)
- Be physically available for the medicine visit in the study area (present to receive it)
- Be at least 6 months old (and meet the specific age rules for each medicine type)
- You must pass safety blood tests, including a hemoglobin level of at least 9 g/dL
- Accept required testing and questions (including G6PD test for some participants and a pregnancy test if applicable)
- Not have taken certain malaria medicines in the last 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two medicines, SJ733 and tafenoquine, to see if it can safely and quickly cure vivax malaria. Vivax malaria can come back, so this treatment aims to prevent that relapse.
This trial tests a shorter course of the drug primaquine to prevent relapse of vivax malaria, a recurring type of malaria. It may offer a faster recovery with fewer doses.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This study tests how the malaria medicine tafenoquine is processed in the bodies of young children with vivax malaria. It helps find the right dose for small children and ensures the treatment is safe and effective.
This study gives healthy adults who have never had malaria a controlled infection with the parasite that causes malaria, to see if it is safe and if mosquitoes can pick up the parasite from them. It may help develop new ways to prevent malaria.
Hear when a new Plasmodium Vivax Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.